Moffitt logo

Clinical Trials Search

Clinical Trial 20866

Cancer Type: Genitourinary
Study Type: Treatment
NCT#: NCT03606174

Phase: Phase II
Principal Investigator:

Call 813-745-6100
or 1-800-679-0775 Learn More

Study Title

A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients with Advanced or Metastatic Urothelial Carcinoma


The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.


- To evaluate the clinical activity of sitravatinib in combination with PD-(L)1 checkpoint inhibitor regimens in patients with advanced or metastatic urothelial carcinoma



Immunotherapy; Therapy (NOS)


BMS-936558 (Nivolumab); Enfortumab Vedotin (Padcev); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Sitravatinib ()

Inclusion Criteria

  • Diagnosis of urothelial carcinoma
  • Adequate bone marrow and organ function

  • Exclusion Criteria

  • Uncontrolled tumor in the brain
  • Unacceptable toxicity with prior checkpoint inhibitor
  • Impaired heart function

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.